Navigation Links
BioMS Medical reports results of exploratory phase II trial of dirucotide in relapsing remitting multiple sclerosis
Date:1/30/2009

Toronto Stock Exchange Symbol: MS

EDMONTON, Jan. 30 /PRNewswire-FirstCall/ - BioMS Medical Corp. (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced results from MINDSET-01, an exploratory phase II clinical trial evaluating dirucotide in patients with relapsing-remitting MS. The lead clinical development program for dirucotide is for secondary progressive MS where it is being evaluated in two ongoing phase III trials in the United States, Canada and Europe, with results from the Canadian and European MAESTRO-01 trial expected in the second half of 2009.

The results of the MINDSET-01 study showed that dirucotide did not meet its primary endpoint, annualized relapse rate or associated secondary MRI endpoints. Dirucotide did meet certain secondary endpoints related to the progression of the disease, including mean change from baseline in the Expanded Disability Status Scale (EDSS) and the Multiple Sclerosis Functional Composite (MSFC) score. The EDSS is a method of quantifying disability in MS, while the MSFC evaluates additional functional parameters. Measuring changes in EDSS and MSFC are primary and secondary outcomes in the ongoing phase III secondary progressive MS trials.

The data also showed that dirucotide was generally well tolerated. The most common side effects reported were redness and burning sensation at the injection site. No patients withdrew due to adverse events.

BioMS and its partner Eli Lilly & Company (Lilly) will continue to analyze the results of this exploratory phase II trial. Under the terms of the licensing agreement with Lilly, no milestone payment was associated with this trial.

"We are encouraged that dirucotide has demonstrated an effect on certain clinical measures of disease progression, this time in the earlier form of the disease," said Kevin Giese, President and CEO of BioMS Medical. "Dirucotide was developed as a potential treatment f
'/>"/>

SOURCE BioMS Medical Corp.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. BioMS Medical recognized at Scrip Awards 2008
2. BioMS Medical Announces Third Quarter 2008 Results
3. BioMS Medical to present at Rodman and Renshaw Annual Healthcare Conference
4. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
5. BioMS Medicals phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
6. BioMS Medical announces receipt of milestone payment from Eli Lilly and Company
7. BioMS Medical to present at Sachs Associates Biotech in Europe Forum
8. BioMS Medical to present at UBS Global Life Sciences Conference
9. BioMS Medicals lead drug, dirucotide (MBP8298) for the treatment of multiple sclerosis, receives fast track designation from FDA
10. BioMS Medical announces its intention to renew a normal course issuer bid
11. BioMS Medical announces positive interim analysis on phase III trial of dirucotide (MBP8298) for multiple sclerosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... Muncie, IN (PRWEB) August 22, 2014 Today ... Review in the United States Court of Appeals for the ... for Model Aircraft published in the Federal Register on June ... Interpretive Rule is contrary to the text and intent of ... 112-95, and violates Congress’ specific prohibition on any new rules ...
(Date:8/22/2014)... published today (August 22nd), in the scientific journal ... Neuroscience Programme establish the effect of serotonin on ... genetic and optical techniques., "Serotonin is a small ... range of brain functions, from the control of ... emotional behaviours, This neurotransmitter is also popularly thought ...
(Date:8/22/2014)... 2014 Ophthalmic drug delivery technologies ... challenging endeavors as the anatomy, physiology and biochemistry ... the foreign substances. Ocular drug delivery technologies provide ... and minimal use of needles; also it enables ... provides specific targeting within the ocular globe. On ...
(Date:8/22/2014)... Research and Markets has announced the addition ... Reagents (Cloning, Epigenetics, PCR, Restriction Digestion, Sequencing) Market - ... The global molecular biology enzymes market was ... to grow at a CAGR of 13.74% to reach ... reagents find applications in a large number of fields ...
Breaking Biology Technology:AMA Files Petition for Review of FAA’s Interpretive Rule 2From happiness to pain: Understanding serotonin's function 2Ocular Drug Delivery Technologies Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 2Ocular Drug Delivery Technologies Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 3Ocular Drug Delivery Technologies Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 4Global Molecular Biology Enzymes, Kits, & Reagents (Cloning, Epigenetics, PCR, Restriction Digestion, Sequencing) Market - Forecast to 2018 2Global Molecular Biology Enzymes, Kits, & Reagents (Cloning, Epigenetics, PCR, Restriction Digestion, Sequencing) Market - Forecast to 2018 3
... ... SCD Probiotics has released a case study that provides ... - with documented evidence of the effectivness of beneficial microbial applications. ... light by the Environmental Protection Agency, who recently agreed to ...
... ... to include one of a kind iron supplement. , ... Las Vegas, NV (PRWEB) June 24, 2010 -- Bariatric Advantage, a ... their new products at the ASMBS conference. The Company located in Booth #115 enjoyed high ...
... 22 As previously announced on October 24th, 2009 delSECUR ... to an Ontario company, QTECH SYSTEMS INC. in exchange for 49% ... appointments to QTECH,s Management Team and the appointment of a new Chief Technology ... , , ...
Cached Biology Technology:Effective Odor and Pathogen Control in Livestock Operations Revealed in New Case Study 2delSECUR CORPORATION Announces Organizational Update as QTECH SYSTEMS INC. Expands Leadership Team 2delSECUR CORPORATION Announces Organizational Update as QTECH SYSTEMS INC. Expands Leadership Team 3
(Date:8/21/2014)... a key region in the global oceanic circulation. "On the ... Atlantic water flows to the north into the Arctic Ocean ... sea ice push their way out of the Arctic into ... cools here on its way to the north and sinks ... this manner drives the global band of oceanic currents like ...
(Date:8/21/2014)... study recently published in the journal Carcinogenesis ... new role for the protein adenomatous polyposis coli (APC) ... cancer-related deaths in the U.S. , Lead author Kristi ... and co-leader of the Cancer Biology program at the ... her career trying to understand the various activities of ...
(Date:8/21/2014)... has successfully replicated one of the crucial steps in ... sunlight which could manufacture hydrogen as a fuel. , ... an exciting prospect to use them to create hydrogen, ... Hingorani, from the ARC Centre of Excellence for Translational ... Hydrogen offers potential as a zero-carbon replacement for petroleum ...
Breaking Biology News(10 mins):Arctic sea ice influenced force of the Gulf Stream 2Arctic sea ice influenced force of the Gulf Stream 3Research offers insight into cellular biology of colorectal cancer 2Research offers insight into cellular biology of colorectal cancer 3Water and sunlight the formula for sustainable fuel 2
... papers that have been recently published in Geophysical Research ... Earth ( JGR-B ) and Journal of Geophysical ... 1. An earthquake in Japan caused large waves in Norwegian ... in Ohio, 3. The Arctic is especially sensitive to black ...
... Johns Hopkins have uncovered a protein switch that can ... depending on the signals it detects. Its dual role ... network of signals that shapes our brain,s circuitry, the ... the July 31 issue of the Journal of ...
... A strain of bacteria that causes skin and soft tissue ... study to be published in mBio , the online ... who conducted the genetic analysis of strains of Staphylococcus ... to methicillin after they crossed over into humans around forty ...
Cached Biology News:AGU journal highlights -- Aug. 13, 2013 2AGU journal highlights -- Aug. 13, 2013 3AGU journal highlights -- Aug. 13, 2013 4AGU journal highlights -- Aug. 13, 2013 5AGU journal highlights -- Aug. 13, 2013 6AGU journal highlights -- Aug. 13, 2013 7AGU journal highlights -- Aug. 13, 2013 8Newly discovered 'switch' plays dual role in memory formation 2MRSA strain in humans originally came from cattle 2MRSA strain in humans originally came from cattle 3
DAPI: 4', 6-Diamino-2-phenylindole dihydrochloride. Antifade Solution: p-Phenylenediamine and glycerol in PBS solution. 0.4g/mL DAPI suspended in Antifade....
Anti-Mouse Qa.m8, Ascites (Clone 5035-24.1) (mouse IgG3)...
... 13(S)-HODE-d4 contains 4 deuterium atoms at the ... intended for use as an internal standard for ... spectrometry. 13(S)-HODE is produced by incubation of linoleic ... been shown to inhibit the adhesion of tumor ...
...
Biology Products: